National Technical Reports Library

The National Technical Information Service acquires, indexes, abstracts, and archives the largest collection of U.S. government-sponsored technical reports in existence. The NTRL offers online, free and open access to these authenticated government technical reports. Technical reports and documents in its repository may be available online for free either from the issuing federal agency, the U.S. Government Publishing Office’s Federal Digital System website, or through search engines.

Details

Guidance for Industry: Statistical Approaches to Establishing Bioequivalence.

PB2010104191

Publication Date	2001
Page Count	48
Abstract	This guidance provides recommendations to sponsors and applicants who intend, either before or after approval, to use equivalence criteria in analyzing in vivo or in vitro bioequivalence (BE) studies for investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs) and supplements to these applications. This guidance discusses three approaches for BE comparisons: average, population, and individual. The guidance focuses on how to use each approach once a specific approach has been chosen. This guidance replaces a prior FDA guidance entitled Statistical Procedures for Bioequivalence Studies Using a Standard Two- Treatment Crossover Design, which was issued in July 1992.
Keywords	Prescription drugs Drugs Statistical models Statistical analysis Population Individual Sample sizes Dropouts Data analysis Recommendations Drug products Logarithmic transformation Bioequivalence Industry guidances New drug applications Food and Drug Administration (FDA)
Source Agency	Food and Drug Administration
Corporate Authors	Food and Drug Administration, Rockville, MD. Center for Drug Evaluation and Research.
Document Type	Technical Report
NTIS Issue Number	201007

Guidance for Industry: Statistical Approaches to Establishing Bioequivalence.

Guidance for Industry: Statistical Approaches to Establishing Bioequivalence.
PB2010104191

Publication Date	2001
Page Count	48
Abstract	This guidance provides recommendations to sponsors and applicants who intend, either before or after approval, to use equivalence criteria in analyzing in vivo or in vitro bioequivalence (BE) studies for investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs) and supplements to these applications. This guidance discusses three approaches for BE comparisons: average, population, and individual. The guidance focuses on how to use each approach once a specific approach has been chosen. This guidance replaces a prior FDA guidance entitled Statistical Procedures for Bioequivalence Studies Using a Standard Two- Treatment Crossover Design, which was issued in July 1992.
Keywords	Prescription drugs Drugs Statistical models Statistical analysis Population Individual Sample sizes Dropouts Data analysis Recommendations Drug products Logarithmic transformation Bioequivalence Industry guidances New drug applications Food and Drug Administration (FDA)
Source Agency	Food and Drug Administration
Corporate Authors	Food and Drug Administration, Rockville, MD. Center for Drug Evaluation and Research.
Document Type	Technical Report
NTIS Issue Number	201007